Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics.
The post Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials appeared first on MedCity News.
